Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Financial Officer | April 22, 2020 | April 24, 2020 |
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director · President & CEO | February 13, 2026 | February 18, 2026 |
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date April 22, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 24,272 |
Ending reported balance
After 2020-04-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-04-22 · Exercise / conversion · Acquired 5,893 · Balance 26,199 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Row 2 · 2020-04-22 · Tax withholding · Disposed 1,927 · Balance 24,272 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 11,785 |
Reported balance
After 2020-04-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-22 · Exercise / conversion · Disposed 5,893 · Balance 11,785 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
C4 Therapeutics, Inc.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,123,145 |
Reported balance
After 2026-02-13 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 700,000 · Balance 1,123,145 F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. |
| Common StockSEC Table I · non-derivative | Direct | 1,123,145 |
Reported balance
After 2026-02-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-02-14 · Exercise / conversion · Acquired 81,725 · Balance 1,123,145 F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 1,083,991 |
Reported balance
After 2026-02-14 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-02-14 · Tax withholding · Disposed 39,154 · Balance 1,083,991 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
| Common StockSEC Table I · non-derivative | Direct | 1,083,991 |
Reported balance
After 2026-02-15 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-02-15 · Exercise / conversion · Acquired 20,400 · Balance 1,083,991 F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 1,074,934 |
Reported balance
After 2026-02-15 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2026-02-15 · Tax withholding · Disposed 9,057 · Balance 1,074,934 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
F2: Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025.
F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Editas Medicine, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2036-06-16 | Direct | 51,700 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,700 · Balance 51,700 F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2020 Filed Feb 19, 2020 21:51 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · derivative · entry 5 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 21:51 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:51 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · derivative · entry 4 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 45,000 shares Expires 2030-02-14 F3 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:51 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000016 · wf-form4_158214909552275.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:31 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $21.74 | $0.00 |
DisclosureSEC source: 0001179110-19-007685 · edgar.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 21:38 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 17,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025785 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,678 Underlying: Common stock · 17,678 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on April 22, 2019. Beginning on April 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013536 · doc4.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $58.86 | $0.00 |
DisclosureSEC source: 0001209191-19-013536 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common stock · 40,000 shares Expires 2029-02-22 F1 · derivative.exercise_date: This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 821 | $58.03 | $47,642.63 |
DisclosureSEC source: 0001209191-19-011491 · doc4.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,374 Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011491 · doc4.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2019 Filed Feb 20, 2019 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-011491 · doc4.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 22, 2019 Filed Jan 23, 2019 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 4,555 | $52.82 | $240,595.10 |
DisclosureSEC source: 0001209191-19-004961 · doc4.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,445 Read SEC document |
| January 20, 2019 Filed Jan 23, 2019 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004961 · doc4.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 20, 2019 Filed Jan 23, 2019 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-004961 · doc4.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 20:34 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantPerformance share units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-043731 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The performance share units were originally granted on September 20, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:04 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $37.50 | $0.00 |
DisclosureSEC source: 0001179110-18-008769 · edgar.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2028-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2018 and is scheduled to vest in full on June 15, 2019. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011246 · doc4.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common stock · 8,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 21:03 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 33,000 | $0.00 Strike: $77.70 | $0.00 |
DisclosureSEC source: 0001209191-18-011246 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common stock · 33,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 30, 2017 Filed May 31, 2017 20:56 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 23,076 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0001179110-17-008256 · edgar.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2027-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2017 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on May 30, 2018 through May 30, 2020. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 21:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 47,600 | $0.00 Strike: $50.40 | $0.00 |
DisclosureSEC source: 0001209191-17-013746 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 Underlying: Common stock · 47,600 shares Expires 2027-02-20 F1 · derivative.exercise_date: This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 20, 2016 Filed Sep 21, 2016 20:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $49.83 | $0.00 |
DisclosureSEC source: 0001209191-16-142264 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common stock · 125,000 shares Expires 2026-09-19 F1 · derivative.exercise_date: This option was granted on September 20, 2016. The shares underlying this option vest as to 25% of the underlying shares on September 19, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.